NASDAQ:HSIC - Henry Schein Stock Price, Price Target & More

Get Started

$71.30 -0.16 (-0.22 %)

(As of 05/22/2018 04:00 PM ET)

Previous Close$71.46

Today's Range$71.05 - $71.69

52-Week Range$62.56 - $93.50

Volume857,400 shs

Average Volume1.86 million shs

Market Capitalization$11.08 billion

P/E Ratio19.84

Dividend YieldN/A

Beta1.04

About Henry Schein (NASDAQ:HSIC)

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides animal health products, such as branded and generic pharmaceuticals, surgical and consumable products and services, and equipment; and medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners, and animal health clinics. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. The company was founded in 1932 and is headquartered in Melville, New York.

Receive HSIC News and Ratings via Email

Sign-up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical & hospital equipment

Sub-IndustryHealth Care Distributors

SectorMedical

SymbolNASDAQ:HSIC

CUSIP80640710

Webwww.henryschein.com

Phone631-843-5500

Debt

Debt-to-Equity Ratio0.34

Current Ratio1.44

Quick Ratio0.74

Price-To-Earnings

Trailing P/E Ratio19.84

Forward P/E Ratio17.39

P/E Growth1.72

Sales & Book Value

Annual Sales$12.46 billion

Price / Sales0.88

Cash Flow$4.8176 per share

Price / Cash14.80

Book Value$18.00 per share

Price / Book3.96

Profitability

EPS (Most Recent Fiscal Year)$3.60

Net Income$406.29 million

Net Margins3.18%

Return on Equity19.68%

Return on Assets7.59%

Miscellaneous

Employees22,000

Outstanding Shares154,020,000

Henry Schein (NASDAQ:HSIC) Frequently Asked Questions

What is Henry Schein's stock symbol?

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

When did Henry Schein's stock split? How did Henry Schein's stock split work?

Henry Schein's stock split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were issued to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

How will Henry Schein's stock buyback program work?

Henry Schein announced that its Board of Directors has approved a stock repurchase program on Tuesday, September 19th 2017, which permits the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 6.3% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's board of directors believes its shares are undervalued.

How were Henry Schein's earnings last quarter?

Henry Schein Inc (NASDAQ:HSIC) issued its quarterly earnings results on Tuesday, May, 8th. The company reported $0.95 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.92 by $0.03. The business earned $3.22 billion during the quarter, compared to the consensus estimate of $3.18 billion. Henry Schein had a return on equity of 19.68% and a net margin of 3.18%. The company's revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.88 earnings per share. View Henry Schein's Earnings History.

What guidance has Henry Schein issued on next quarter's earnings?

Henry Schein updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $4.03-4.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.09.

What price target have analysts set for HSIC?

19 analysts have issued twelve-month price objectives for Henry Schein's shares. Their forecasts range from $73.00 to $102.00. On average, they expect Henry Schein's stock price to reach $81.50 in the next year. View Analyst Ratings for Henry Schein.

What are Wall Street analysts saying about Henry Schein stock?

Here are some recent quotes from research analysts about Henry Schein stock:

1. Barrington Research analysts commented, "We are currently modeling $4.08. It is important to note that management’s adjusted EPS guidance does not include any impact from the upcoming animal health spin-off and merger, which is expected to occur before year end. In addition, the guidance does not factor in any future M&A activity." (5/10/2018)
2. According to Zacks Investment Research, "Henry Schein exited first-quarter 2018 on a strong note with earnings and revenues steering past the Zacks Consensus Estimate. All four operating segments recorded strong year-over-year growth. Henry Schein's strong share gains in the North American and overseas markets along with solid revenues raise optimism. Despite the better-than-expected revenue performance, we are disappointed with the year-over-year deterioration in Henry Schein's gross and operating margin due to higher costs and expenses. We currently await the completion of the company’s global Animal Health business' planned spin-off. This business contributes nearly 30% to the company’s topline. The spin off is expected to bring in major changes to Henry Schein’s overall operating results. On the flip side, pricing pressure and tough competition are major woes. Overall, in the past three months, Henry Schein has outperformed the broader industry." (5/10/2018)

Are investors shorting Henry Schein?

Henry Schein saw a increase in short interest in April. As of April 13th, there was short interest totalling 21,095,702 shares, an increase of 6.5% from the March 30th total of 19,816,414 shares. Based on an average daily volume of 1,470,012 shares, the days-to-cover ratio is presently 14.4 days. Currently, 14.0% of the shares of the stock are sold short.

Who are some of Henry Schein's key competitors?

Some companies that are related to Henry Schein include Express Scripts (ESRX), Boston Scientific (BSX), Zoetis (ZTS), Beximco Pharmaceuticals (BXP), Humana (HUM), Vertex Pharmaceuticals (VRTX), Illumina (ILMN), Baxter International (BAX), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Fresenius Medical Care (FMS), Astellas Pharma (ALPMY), McKesson (MCK) and Essilor International (ESLOY).

Who are Henry Schein's key executives?

Henry Schein's management team includes the folowing people:

Mr. Stanley M. Bergman, Exec. Chairman & CEO (Age 68)
Mr. James P. Breslawski, Vice Chairman & Pres (Age 64)
Mr. Steven Paladino, Exec. VP, CFO & Exec. Director (Age 61)
Mr. Gerald A. Benjamin, Exec. VP, Chief Admin. Officer & Director (Age 65)
Mr. Robert Minowitz, Sr. VP of Global Dental Merchandising & Bus. Operations (Age 59)

Has Henry Schein been receiving favorable news coverage?

Media headlines about HSIC stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Henry Schein earned a news impact score of 0.19 on Accern's scale. They also gave news articles about the company an impact score of 45.51 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are Henry Schein's major shareholders?

Henry Schein's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.50%), Select Equity Group L.P. (4.20%), Alecta Pensionsforsakring Omsesidigt (3.57%), JPMorgan Chase & Co. (1.66%), Atlanta Capital Management Co. L L C (1.61%) and Swedbank (1.41%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

Which major investors are selling Henry Schein stock?

HSIC stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Green Valley Investors LLC, BlackRock Inc., Virginia Retirement Systems ET AL, Glen Harbor Capital Management LLC, Neuberger Berman Group LLC, Russell Investments Group Ltd. and Swedbank. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin and Paul Rose. View Insider Buying and Selling for Henry Schein.

Which major investors are buying Henry Schein stock?

HSIC stock was acquired by a variety of institutional investors in the last quarter, including Select Equity Group L.P., American Century Companies Inc., Kovitz Investment Group Partners LLC, Wells Fargo & Company MN, Alecta Pensionsforsakring Omsesidigt, New York State Common Retirement Fund, The Manufacturers Life Insurance Company and Public Employees Retirement Association of Colorado. View Insider Buying and Selling for Henry Schein.

How do I buy shares of Henry Schein?

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Henry Schein's stock price today?

One share of HSIC stock can currently be purchased for approximately $71.30.

How big of a company is Henry Schein?

Henry Schein has a market capitalization of $11.08 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

How can I contact Henry Schein?

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]

MarketBeat Community Rating for Henry Schein (HSIC)

Community Ranking:		1.7 out of 5 ()
Outperform Votes:		193 (Vote Outperform)
Underperform Votes:		379 (Vote Underperform)
Total Votes:		572

MarketBeat's community ratings are surveys of what our community members think about Henry Schein and other stocks. Vote "Outperform" if you believe HSIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSIC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Henry Schein (NASDAQ:HSIC) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

19 Wall Street analysts have issued ratings and price targets for Henry Schein in the last 12 months. Their average twelve-month price target is $81.50, suggesting that the stock has a possible upside of 14.31%. The high price target for HSIC is $102.00 and the low price target for HSIC is $73.00. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.42	2.44	2.44	2.47
Ratings Breakdown:	1 Sell Rating(s) 9 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 8 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 7 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$81.50	$82.3125	$83.5714	$89.8846
Price Target Upside:	14.31% upside	23.15% upside	21.68% upside	28.33% upside

Henry Schein (NASDAQ:HSIC) Consensus Price Target History

Price Target History for Henry Schein (NASDAQ:HSIC)

Henry Schein (NASDAQ:HSIC) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/10/2018	Barrington Research	Lower Price Target	Outperform	$88.00	Low
5/9/2018	Barclays	Reiterated Rating	Hold	$73.00	Low
4/24/2018	Northcoast Research	Set Price Target	Buy	$102.00	Low
4/24/2018	Deutsche Bank	Boost Price Target	Buy ➝ Buy	$79.00 ➝ $82.00	High
4/24/2018	Goldman Sachs	Downgrade	Buy ➝ Neutral		High
4/4/2018	Leerink Swann	Upgrade	Market Perform ➝ Outperform	$75.00	High
2/27/2018	Bank of America	Initiated Coverage	Neutral ➝ Neutral	$76.00	Low
2/15/2018	JPMorgan Chase	Reiterated Rating	Neutral ➝ Neutral	$79.00 ➝ $77.00	Low
1/4/2018	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$81.00	Medium
12/27/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$78.00	Low
12/6/2017	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$88.00	High
11/28/2017	Credit Suisse Group	Reiterated Rating	Neutral	$87.50 ➝ $80.00	Low
11/28/2017	Stephens	Initiated Coverage	Equal ➝ Equal Weight	$76.00	Low
11/7/2017	Jefferies Group	Lower Price Target	Hold	$89.00 ➝ $74.00	N/A
11/7/2017	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$89.00 ➝ $77.00	N/A
11/7/2017	Craig Hallum	Upgrade	Hold ➝ Buy		N/A
11/7/2017	Royal Bank of Canada	Lower Price Target	Sector Perform ➝ Sector Perform	$91.00 ➝ $82.00	N/A
10/19/2017	Robert W. Baird	Set Price Target	Buy	$95.00	N/A
9/15/2017	UBS	Reiterated Rating	Buy		N/A
1/10/2017	Gabelli	Upgrade	Hold ➝ Buy	$104.00	N/A

(Data available from 5/22/2016 forward)

Henry Schein (NASDAQ:HSIC) Earnings History and Estimates Chart

Earnings by Quarter for Henry Schein (NASDAQ:HSIC)

Henry Schein (NASDAQ:HSIC) Earnings Estimates

2018 EPS Consensus Estimate: $4.10
2019 EPS Consensus Estimate: $4.50

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	6	$0.91	$0.96	$0.93
Q2 2018	6	$1.00	$1.02	$1.01
Q3 2018	6	$1.00	$1.04	$1.02
Q4 2018	6	$1.12	$1.18	$1.14
Q1 2019	3	$1.00	$1.05	$1.02
Q2 2019	3	$1.08	$1.10	$1.09
Q3 2019	3	$1.11	$1.14	$1.13
Q4 2019	3	$1.25	$1.27	$1.26

Henry Schein (NASDAQ HSIC) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018	Q1 2018	$0.92	$0.95	$3.1765 billion	$3.2204 billion	View	N/A
2/20/2018	Q4 2017	$0.97	$0.97	$3.3037 billion	$3.3181 billion	View	Listen
11/6/2017	Q3 2017	$0.90	$0.87	$3.0496 billion	$3.1611 billion	View	N/A
8/8/2017	Q2 17	$0.8650	$0.8750	$3.0525 billion	$3.0595 billion	View	Listen
5/9/2017	Q1 17	$0.8250	$0.88	$2.8334 billion	$2.9230 billion	View	Listen
2/21/2017	Q416	$0.9250	$0.94	$3.08 billion	$3.1209 billion	View	Listen
11/2/2016	Q316	$0.8250	$0.84	$2.88 billion	$2.8652 billion	View	N/A
8/4/2016	Q216	$0.8150	$0.82	$2.85 billion	$2.87 billion	View	N/A
5/3/2016	Q116	$0.6950	$0.7050	$2.66 billion	$2.70 billion	View	Listen
2/10/2016	Q415	$0.8250	$0.8350	$2.82 billion	$2.90 billion	View	Listen
11/4/2015	Q315	$0.7350	$0.7750	$2.70 billion	$2.70 billion	View	Listen
7/29/2015	Q215	$0.73	$0.73	$2.68 billion	$2.60 billion	View	Listen
5/4/2015	Q1	$0.6350	$0.64	$2.54 billion	$25.00 billion	View	Listen
2/11/2015	Q414	$0.7550	$0.78	$2.72 billion	$2.70 billion	View	Listen
11/6/2014	Q314	$0.6550	$0.67	$2.55 billion	$2.6237 billion	View	Listen
8/4/2014	Q214	$0.6650	$0.6750	$2.56 billion	$2.60 billion	View	Listen
5/6/2014	Q1	$0.5650	$0.59	$2.43 billion	$2.40 billion	View	Listen
2/11/2014	Q413	$0.6950	$0.7150	$2.53 billion	$2.50 billion	View	Listen
11/5/2013	Q313	$0.6050	$0.61	$2.37 billion	$2.30 billion	View	Listen
8/6/2013	Q2 2013	$0.6150	$0.6150	$2.39 billion	$2.40 billion	View	Listen
5/7/2013	Q1 2013	$0.5350	$0.53	$2.25 billion	$2.30 billion	View	Listen
2/13/2013	Q4 2012	$0.6050	$0.63	$2.40 billion	$2.40 billion	View	Listen
11/7/2012	Q312	$0.5350	$0.54	$2.24 billion	$2.2311 billion	View	N/A
8/2/2012		$0.55	$0.5550			View	N/A
5/8/2012		$0.46	$0.49			View	N/A
2/15/2012		$0.56	$0.5750			View	N/A
11/1/2011		$0.50	$0.4950			View	N/A
8/2/2011		$0.50	$0.5050			View	N/A
5/3/2011		$0.40	$0.41			View	N/A
2/22/2011		$0.48	$0.50			View	N/A
10/29/2010	Q3 2010	$0.44	$0.47			View	N/A
8/2/2010	Q2 2010	$0.43	$0.45			View	N/A
5/4/2010	Q1 2010	$0.35	$0.37			View	N/A
2/23/2010	Q4 2009	$0.46	$0.47			View	N/A
11/4/2009	Q3 2009	$0.41	$0.40			View	N/A
8/4/2009	Q2 2009	$0.38	$0.41			View	N/A
5/4/2009	Q1 2009	$0.29	$0.32			View	N/A
2/24/2009	Q4 2008	$0.44	$0.45			View	N/A
11/5/2008	Q3 2008	$0.38	$0.39			View	N/A
8/5/2008	Q2 2008	$0.34	$0.36			View	N/A
5/6/2008	Q1 2008	$0.28	$0.28			View	N/A
2/25/2008	Q4 2007	$0.41	$0.42			View	N/A

(Earnings results data provided by Zacks Investment Research)

Henry Schein (NASDAQ:HSIC) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Henry Schein (NASDAQ HSIC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.15%
Institutional Ownership Percentage: 95.58%

Insider Trading History for Henry Schein (NASDAQ:HSIC)

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Henry Schein (NASDAQ HSIC) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2017	Barry J Alperin	Director	Sell	5,796	$70.76	$410,124.96	48,172
9/6/2017	Paul Rose	SVP	Sell	2,126	$172.51	$366,756.26	17,841
5/11/2017	Gerald A Benjamin	EVP	Sell	12,578	$175.10	$2,202,407.80	44,061
3/23/2017	Lorelei Mcglynn	SVP	Sell	9,300	$171.76	$1,597,368.00	33,048
3/20/2017	Michael Racioppi	SVP	Sell	9,969	$171.69	$1,711,577.61	33,057
3/17/2017	Mark E Mlotek	EVP	Sell	5,559	$170.98	$950,477.82	40,426
3/8/2017	James A Harding	SVP	Sell	10,552	$171.60	$1,810,723.20	21,118
3/8/2017	Philip A Laskawy	Director	Sell	1,103	$171.51	$189,175.53	13,872
3/2/2017	Michael S Ettinger	SVP	Sell	6,960	$171.09	$1,190,786.40	31,308
2/27/2017	Donald J Kabat	Director	Sell	4,334	$173.62	$752,469.08	10,729
2/22/2017	Paul Rose	SVP	Sell	6,821	$173.24	$1,181,670.04	24,674
2/22/2017	Steven Paladino	CFO	Sell	13,072	$173.40	$2,266,684.80	76,433
12/12/2016	Kurt P Kuehn	Director	Buy	1,000	$151.41	$151,410.00	2,039
11/3/2016	Mark E Mlotek	EVP	Sell	2,417	$155.19	$375,094.23	40,456
8/29/2016	Paul Brons	Director	Sell	3,381	$164.03	$554,585.43	13,715
6/2/2016	Gerald A Benjamin	EVP	Sell	9,991	$175.08	$1,749,224.28	54,885
5/16/2016	James A Harding	SVP	Sell	10,302	$172.60	$1,778,125.20	21,933
5/12/2016	Peter M Mccarthy	Insider	Sell	1,158	$171.75	$198,886.50	12,285
3/15/2016	Lonnie Shoff	CEO	Sell	3,028	$168.29	$509,582.12	31,000
3/14/2016	David Mckinley	Insider	Sell	3,339	$167.92	$560,684.88	27,645
3/14/2016	Norman S Matthews	Director	Sell	5,335	$167.75	$894,946.25	15,425
3/10/2016	Donald J Kabat	Director	Sell	1,218	$168.38	$205,086.84	3,189
3/7/2016	Barry J Alperin	Director	Sell	1,635	$167.36	$273,633.60	24,322
3/7/2016	Michael S Ettinger	SVP	Sell	5,423	$168.13	$911,768.99	32,286
3/4/2016	Philip A Laskawy	Director	Sell	1,317	$166.88	$219,780.96	17,294
3/2/2016	Louis W Sullivan	Director	Sell	11,735	$168.59	$1,978,403.65	16,830
3/2/2016	Mark E Mlotek	EVP	Sell	4,982	$167.93	$836,627.26	45,149
2/26/2016	Barry J Alperin	Director	Sell	7,540	$167.96	$1,266,418.40	33,294
2/24/2016	Robert Minowitz	Insider	Sell	9,648	$165.48	$1,596,551.04	25,788
2/22/2016	Michael Racioppi	SVP	Sell	21,567	$166.74	$3,596,081.58	49,866
2/17/2016	Stanley Komaroff	Insider	Sell	8,000	$163.53	$1,308,240.00	31,694
2/16/2016	Norman S Matthews	Director	Sell	4,230	$160.05	$677,011.50	17,122
2/12/2016	Steven Paladino	CFO	Sell	11,727	$157.21	$1,843,601.67	83,602
2/11/2016	Donald J. Kabat	Director	Sell	6,637	$156.36	$1,037,761.32	5,938
12/17/2015	Michael Racioppi	SVP	Sell	9,901	$155.92	$1,543,763.92	28,299
12/10/2015	Stanley M. Bergman	CEO	Sell	61,800	$155.45	$9,606,810.00	152,926
11/9/2015	Paul Rose	SVP	Sell	3,638	$151.92	$552,684.96	19,223
11/5/2015	Mark E. Mlotek	EVP	Sell	2,952	$155.00	$457,560.00	46,116
11/5/2015	Stanley Komaroff	Insider	Sell	6,297	$154.89	$975,342.33	39,694
9/16/2015	Philip A Laskawy	Director	Sell	4,000	$136.20	$544,800.00	16,191
5/6/2015	Paul Brons	Director	Sell	3,801	$136.70	$519,596.70
3/19/2015	Michael S Ettinger	SVP	Sell	4,352	$139.75	$608,192.00
3/18/2015	James P Breslawski	CEO	Sell	12,811	$139.45	$1,786,493.95
3/17/2015	Leonard A David	SVP	Sell	3,935	$140.00	$550,900.00
3/16/2015	Paul Rose	SVP	Sell	3,264	$140.13	$457,384.32
3/13/2015	Norman S Matthews	Director	Sell	9,200	$136.07	$1,251,844.00
3/11/2015	Philip A Laskawy	Director	Sell	2,669	$136.60	$364,585.40
3/10/2015	Donald J Kabat	Director	Sell	2,002	$138.00	$276,276.00
3/5/2015	Barry J Alperin	Director	Sell	6,637	$140.64	$933,427.68
2/24/2015	Stanley Komaroff	Insider	Sell	8,000	$141.69	$1,133,520.00
2/12/2015	Donald J Kabat	Director	Sell	5,000	$142.68	$713,400.00
2/12/2015	Gerald A Benjamin	EVP	Sell	22,116	$142.71	$3,156,174.36
2/12/2015	Robert Minowitz	Insider	Sell	11,254	$142.63	$1,605,158.02
12/18/2014	Leonard A David	SVP	Sell	3,557	$135.34	$481,404.38
12/9/2014	Stanley M Bergman	CEO	Sell	69,600	$135.56	$9,434,976.00
12/8/2014	Stanley M Bergman	CEO	Sell	23,485	$136.34	$3,201,944.90
11/24/2014	Stanley Komaroff	Insider	Sell	13,757	$133.06	$1,830,506.42
11/7/2014	Lorelei Mcglynn	SVP	Sell	15,746	$129.03	$2,031,706.38
11/7/2014	Mark E Mlotek	EVP	Sell	6,262	$128.75	$806,232.50
9/2/2014	Philip A Laskawy	Director	Sell	15,438	$119.40	$1,843,297.20
8/29/2014	Louis W Sullivan	Director	Sell	17,262	$119.99	$2,071,267.38
6/9/2014	Barry J Alperin	Director	Sell	7,500	$120.39	$902,925.00
6/2/2014	Gerald A Benjamin	EVP	Sell	12,354	$119.50	$1,476,303.00
5/28/2014	Norman S Matthews	Director	Sell	6,637	$118.68	$787,679.16
5/19/2014	Donald Kabat	Director	Sell	5,000	$116.30	$581,500.00	8,851
5/15/2014	Paul Brons	Director	Sell	5,363	$113.77	$610,148.51	13,851
3/19/2014	Barry Alperin	Director	Sell	7,500	$119.18	$893,850.00	25,104
3/17/2014	Lonnie Shoff	CEO	Sell	3,722	$119.06	$443,141.32	31,267
3/12/2014	Michael Ettinger	SVP	Sell	3,537	$119.20	$421,610.40	31,760
3/11/2014	David Mckinley	Insider	Sell	2,387	$119.65	$285,604.55	28,526
3/11/2014	James Breslawski	CEO	Sell	72,642	$119.35	$8,669,822.70	113,936
3/11/2014	Paul Rose	SVP	Sell	3,783	$119.72	$452,900.76	20,229
3/10/2014	Robert Minowitz	Insider	Sell	11,553	$119.98	$1,386,128.94	27,756
3/4/2014	Donald Kabat	Director	Sell	5,000	$119.15	$595,750.00	12,159
2/28/2014	Michael Racioppi	SVP	Sell	18,614	$118.91	$2,213,390.74	30,667
2/26/2014	Stanley Komaroff	Insider	Sell	18,000	$119.36	$2,148,480.00	59,796
2/25/2014	Mark Mlotek	EVP	Sell	20,333	$119.16	$2,422,880.28	52,899
2/20/2014	Steven Paladino	CFO	Sell	28,757	$117.79	$3,387,287.03	88,276
2/12/2014	Philip Laskawy	Director	Sell	5,851	$114.91	$672,338.41	15,982
12/19/2013	Mark Mlotek	EVP	Sell	22,004	$111.97	$2,463,787.88	53,454
12/19/2013	Michael Racioppi	SVP	Sell	29,257	$111.97	$3,275,906.29	26,036
12/17/2013	Gerald Benjamin	EVP	Sell	41,664	$111.66	$4,652,202.24	66,887
12/17/2013	James Breslawski	CEO	Sell	57,754	$111.91	$6,463,250.14	118,030
12/16/2013	Steven Paladino	CFO	Sell	47,652	$112.31	$5,351,796.12	88,276
12/13/2013	Stanley Bergman	CEO	Sell	78,000	$111.90	$8,728,200.00	163,770
12/6/2013	Leonard David	SVP	Sell	13,968	$113.14	$1,580,339.52	20,620
11/26/2013	Stanley Komaroff	Insider	Sell	22,329	$114.79	$2,563,145.91	59,796
8/23/2013	Philip Laskawy	Director	Sell	21,637	$103.17	$2,232,289.29	21,833
8/22/2013	Norman Matthews	Director	Sell	9,851	$103.95	$1,024,011.45	21,782
8/20/2013	Louis Sullivan	Director	Sell	15,000	$103.91	$1,558,650.00	20,987
8/12/2013	Donald Kabat	Director	Sell	2,500	$106.25	$265,625.00	10,598
6/18/2013	Barry J Alperin	Director	Sell	7,500	$97.74	$733,050.00
5/8/2013	James A Harding	CTO	Sell	12,000	$92.64	$1,111,680.00
3/8/2013	Donald J Kabat	Director	Sell	4,038	$90.00	$363,420.00
12/4/2012	Donald J Kabat	Director	Sell	15,000	$80.04	$1,200,600.00

(Data available from 1/1/2013 forward)

Henry Schein (NASDAQ HSIC) News Headlines

Source:

Date	Headline
	BRIEF-Henry Schein Inc Obtained $400 Million Unsecured Loan www.reuters.com - May 22 at 9:03 AM
	Henry Schein Rises To #238 On The FORTUNE 500® finance.yahoo.com - May 21 at 4:37 PM
	[$$] Al Gore's Firm Deletes Facebook, Sells Amazon finance.yahoo.com - May 18 at 9:49 AM
	$3.30 Billion in Sales Expected for Henry Schein Inc (HSIC) This Quarter www.americanbankingnews.com - May 17 at 2:38 AM
	Henry Schein (HSIC) Stock Rating Upgraded by TheStreet www.americanbankingnews.com - May 16 at 3:08 PM
	Henry Schein Inc (HSIC) Expected to Announce Earnings of $1.01 Per Share www.americanbankingnews.com - May 15 at 5:19 PM
	Henry Schein Stock Gets a Quant Upgrade and Sports a Developing Bottom finance.yahoo.com - May 15 at 5:04 PM
	Amid conflict, Jews and Muslims in US seek solidarity finance.yahoo.com - May 15 at 9:39 AM
	Edited Transcript of HSIC earnings conference call or presentation 8-May-18 2:00pm GMT finance.yahoo.com - May 14 at 4:43 PM
	Q2 2018 Earnings Estimate for Henry Schein Inc Issued By Barrington Research (HSIC) www.americanbankingnews.com - May 14 at 2:20 AM
	Q2 2018 EPS Estimates for Henry Schein Inc Lifted by Analyst (HSIC) www.americanbankingnews.com - May 14 at 2:20 AM
	Henry Schein Inc Expected to Earn Q4 2018 Earnings of $1.12 Per Share (HSIC) www.americanbankingnews.com - May 11 at 11:02 AM
	Henry Schein (HSIC) PT Lowered to $88.00 at Barrington Research www.americanbankingnews.com - May 10 at 5:15 PM
	Henry Schein (HSIC) Downgraded by Zacks Investment Research to "Hold" www.americanbankingnews.com - May 10 at 1:02 PM
	Henry Schein Inc (HSIC) Expected to Earn Q3 2018 Earnings of $1.00 Per Share www.americanbankingnews.com - May 10 at 7:50 AM
	Q2 2018 EPS Estimates for Henry Schein Inc Increased by William Blair (HSIC) www.americanbankingnews.com - May 10 at 7:04 AM
	Henry Schein (HSIC) Rating Reiterated by Barclays www.americanbankingnews.com - May 9 at 3:12 PM
	Henry Schein's (HSIC) Q1 Earnings Beat, '18 View Intact finance.yahoo.com - May 9 at 9:15 AM
	Henry Schein (HSIC) Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 9 at 9:15 AM
	Henry Schein (HSIC) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS www.americanbankingnews.com - May 8 at 2:23 PM
	Henry Schein (HSIC) Releases FY18 Earnings Guidance www.americanbankingnews.com - May 8 at 9:16 AM
	Form 8-K HENRY SCHEIN INC For: May 08 www.streetinsider.com - May 8 at 9:09 AM
	Henry Schein profit hit by higher costs www.marketwatch.com - May 8 at 9:09 AM
	Henry Schein beats by $0.03, beats on revenue seekingalpha.com - May 8 at 9:09 AM
	Henry Schein's (HSIC) Q1 Earnings & Revenues Top Estimates www.zacks.com - May 8 at 9:09 AM
	Medical Product Stocks May 8 Earnings List: HSIC, PEN & More finance.yahoo.com - May 8 at 9:09 AM
	Henry Schein: 1Q Earnings Snapshot finance.yahoo.com - May 8 at 9:09 AM
	Henry Schein Reports Record First Quarter 2018 Financial Results finance.yahoo.com - May 8 at 9:09 AM
	Henry Schein's (HSIC) Q1 Earnings & Revenues Top Estimates finance.yahoo.com - May 8 at 9:09 AM
	Northcoast Research Analysts Increase Earnings Estimates for Henry Schein Inc (HSIC) www.americanbankingnews.com - May 8 at 7:34 AM
	Can Overall Growth Drive Henry Schein's (HSIC) Q1 Earnings? finance.yahoo.com - May 7 at 4:50 PM
	DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Henry Schein, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - HSIC finance.yahoo.com - May 7 at 4:50 PM
	DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Henry Schein, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm finance.yahoo.com - May 7 at 4:50 PM
	FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Henry Schein, Inc. (HSIC) & Lead Plaintiff Deadline: May 7, 2018 finance.yahoo.com - May 7 at 4:50 PM
	Can Overall Growth Drive Henry Schein's (HSIC) Q1 Earnings? www.zacks.com - May 7 at 9:04 AM
	HENRY SCHEIN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action ... www.businesswire.com - May 5 at 9:28 AM
	HENRY SCHEIN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Henry Schein, Inc. - HSIC finance.yahoo.com - May 5 at 9:28 AM
	Pawar Law: Important May 7, 2018 Lead Plaintiff Deadline in Henry Schein, Inc. Class Action - HSIC finance.yahoo.com - May 4 at 4:38 PM
	DEADLINE MONDAY: The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Henry Schein, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (HSIC) finance.yahoo.com - May 4 at 4:38 PM
	Henry Schein Introduces Proprietary SLX™ Clear Aligner System www.bizjournals.com - May 4 at 9:08 AM
	Schein introduces new orthodontic system seekingalpha.com - May 4 at 9:08 AM
	Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Henry Schein, Inc. (HSIC) finance.yahoo.com - May 4 at 9:07 AM
	Henry Schein (HSIC) Downgraded by ValuEngine to "Strong Sell" www.americanbankingnews.com - May 4 at 12:41 AM
	MONDAY DEADLINE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Henry Schein, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm finance.yahoo.com - May 3 at 4:38 PM
	Kessler Topaz Meltzer & Check, Llp: Final Deadline Reminder For Henry Schein, Inc. Shareholders - HSIC finance.yahoo.com - May 3 at 4:38 PM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Henry Schein, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 finance.yahoo.com - May 3 at 4:38 PM
	5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Henry Schein, Inc. and Reminds Investors With Losses in Excess of $50,000 to Contact The Firm finance.yahoo.com - May 2 at 4:45 PM
	Brad Connett Named President, U.S. Medical Group At Henry Schein, Inc. finance.yahoo.com - May 2 at 9:10 AM
	The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Henry Schein, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (HSIC) finance.yahoo.com - May 1 at 4:36 PM
	Henry Schein President James Breslawski Assumes New Role As Vice Chairman finance.yahoo.com - May 1 at 9:13 AM

Henry Schein (NASDAQ:HSIC) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Henry Schein (NASDAQ:HSIC) Income Statement, Balance Sheet and Cash Flow Statement

Henry Schein (NASDAQ HSIC) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff